{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:17:48Z","timestamp":1744165068982},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,3,20]],"date-time":"2002-03-20T00:00:00Z","timestamp":1016582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2002,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report here on 2 patients who received adjuvant vaccination with an HLA\u2010A2\u2013 or HLA\u2010A24\u2013restricted tyrosinase peptide, respectively, and GM\u2010CSF for frequently relapsing stage IV melanoma. Following resection of metastases and irradiation of brain metastases in 1 patient, both patients were without evidence of disease when receiving the first vaccination. While the patients had had 9 and 12, respectively, mostly s.c., relapses during the 3 years before vaccination, they experienced freedom from relapse for more than 2 years after vaccination. We found a T\u2010cell response to the vaccine peptide in both patients in the peripheral blood by <jats:italic>ex vivo<\/jats:italic> IFN\u2010\u03b3 ELISPOT assay. The T\u2010cell population could be further characterized by 4\u2010color flow cytometry in 1 patient, showing that the majority of the peptide\u2010specific CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>IFN\u2010\u03b3<jats:sup>+<\/jats:sup> T cells were granzyme B\u2010positive and CCR\u20107\u2010negative, characterizing them as effector T cells with the ability to mediate cytotoxicity and migrate to inflamed tissues. In this patient also, augmentation of the T\u2010cell response to autologous tumor cells by vaccination could be detected. A single\u2010site postvaccination relapse occurred in both patients, showing downregulation of tyrosinase expression in 1 patient, while normal expression levels for tyrosinase, MHC class I antigens and components of the antigen\u2010processing machinery were found in the other patient. These results suggest that peptide vaccination resulted in a prolonged relapse\u2010free interval in these high\u2010risk patients. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.10328","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:45:33Z","timestamp":1030319133000},"page":"403-408","source":"Crossref","is-referenced-by-count":17,"title":["Long\u2010term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides"],"prefix":"10.1002","volume":"99","author":[{"given":"Carmen","family":"Scheibenbogen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Nagorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schmittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Letsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Max","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhard","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-321"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960703)67:1<54::AID-IJC11>3.0.CO;2-C"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199909000-00007"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200003000-00012"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K"},{"key":"e_1_2_6_8_2","first-page":"2756","article-title":"Phase I trial of a MART\u20101 peptide vaccine with incomplete Freund's adjuvant for resected high\u2010risk melanoma","volume":"5","author":"Wang F","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.4049\/jimmunol.163.11.6292","article-title":"Increased vaccine\u2010specific T cell frequency after peptide\u2010based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression","volume":"163","author":"Lee KH","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199705000-00002"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60911-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(00)01692-3"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2913"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.2.527"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4049\/jimmunol.155.3.1343","article-title":"Identification of a tyrosinase epitope recognized by HLA\u2010A24\u2013restricted, tumor\u2010infiltrating lymphocytes","volume":"155","author":"Kang X","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(00)00257-X"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000901)87:5<659::AID-IJC7>3.0.CO;2-7"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(01)00312-X"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/44385"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-59537-0_3"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702363"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000801)87:3<349::AID-IJC7>3.0.CO;2-O"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3836"},{"key":"e_1_2_6_24_2","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100 280\u2013288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome","volume":"7","author":"Slingluff C","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_25_2","first-page":"6451","article-title":"Immune and clinical responses in patients vaccinated with metastatic melanoma to CD34+ progenitor\u2010derived dendritic cell vaccine","volume":"61","author":"Banchereau J","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.5.625"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.4.2287"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.6.3492"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.10328","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.10328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T01:22:31Z","timestamp":1696900951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.10328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,25]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,5,20]]}},"alternative-id":["10.1002\/ijc.10328"],"URL":"https:\/\/doi.org\/10.1002\/ijc.10328","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4,25]]}}}